Yes. Brown skin needs sunscreen, because melanin absorbs only part of the ultraviolet spectrum and leaves real gaps in protection. Melanin filters UV well enough to slow damage, not to stop it. People with brown skin still develop skin cancer, often on sun-exposed sites and often at later, harder-to-treat stages. The practical target is daily broad-spectrum sunscreen on exposed skin, paired with shade and clothing, not a higher SPF number chosen by skin tone.
How melanin actually blocks ultraviolet light
Melanin is not a single substance. Eumelanin, the brown-black pigment that predominates in darker skin, is a large polymer built from oxidized tyrosine units. It absorbs photons across ultraviolet and visible wavelengths and dissipates that energy as heat. Pheomelanin, the red-yellow pigment, absorbs less efficiently and can generate reactive oxygen species when struck by UV. Skin tone reflects the ratio and total amount of both.
The absorption is broad but incomplete. Eumelanin is most effective in the UVB band and short-wavelength UVA. Protection falls off in longer UVA, the range that penetratesdeep into the dermis and drives photoaging. In optical terms, melanin acts like a neutral-density filter with a sloped transmission curve, not a cutoff filter. It reduces dose everywhere and eliminates it nowhere.
The pigment also sits in a physical location that matters. Melanin is packaged in melanosomes and distributed to keratinocytes in the epidermis, forming what researchers describe as a supranuclear cap over the cell nucleus. That cap shields DNA from direct UV hits. But the epidermis is thin, and UV that passes the basal layer reaches fibroblasts and collagen in the dermis, where melanin offers no shield at all.
A useful way to think about it: melanin is built-in shade, and shade is not the same as a wall.
Quantifying the protection gap
The most cited number in this field is the sun protection factor, or SPF, of constitutively dark skin. Estimates cluster around SPF 13 for deeply pigmented skin, derived from the ratio of UV dose needed to produce minimal erythema in protected versus unprotected skin. That is a real barrier. It is also far below the SPF 30 threshold regulators use to define adequate sunscreen protection.
An SPF of 13 blocks roughly 92 percent of the UVB that would otherwise reach the skin. Sounds strong until you run the arithmetic on exposure. A person who would burn in 20 minutes unprotected reaches the erythema threshold in about 260 minutes with that built-in factor. Add sweating, swimming, cloud cover changes, and the fact that erythema is a crude endpoint, and the margin shrinks fast.
The gap widens for UVA. Melanin's protection against UVA is weaker than against UVB, so the pigment's implicit SPF overstates its UVA defense. That matters because UVA drives pigmentary disorders, photoaging, and a meaningful share of DNA damage through indirect oxidative mechanisms. The FDA's broad-spectrum labeling standard exists precisely because SPF alone says nothing about UVA.
Skin cancer statistics make the same point from the other direction. Melanoma incidence in Black Americans is lower than in White Americans but not zero, and survival is worse. Hispanic and Asian American populations show similar patterns of later-stage diagnosis. The mechanism is not that melanin fails completely. It is that partial protection plus delayed detection plus lesions in atypical locations produces worse outcomes per case.
Where brown skin is most vulnerable
Sun exposure is not uniform across the body, and neither is melanoma risk in darker skin. Acral lentiginous melanoma, the subtype most common in Black and Asian populations, arises on palms, soles, and under nails, sites with little cumulative sun exposure. Its relationship to UV is weak or absent. This is the counterintuitive detail that reframes the whole question.
Sunscreen does not prevent acral melanoma. No topical product reaches the nail matrix or the glabrous skin of the sole in a way that meaningfully alters UV dose there, and the etiology appears driven by other factors. Anyone who claims daily sunscreen eliminates skin cancer risk in brown skin is overselling the intervention. Sunscreen addresses UV-driven cancers and pigmentary damage. It is one tool, not a guarantee.
The UV-driven risks in brown skin concentrate where pigment is thinnest or absent. The lips, the ears, the scalp along a part line, the dorsal hands, and the neck are common sites for squamous cell carcinoma and basal cell carcinoma in people with darker skin. Squamous cell carcinoma in particular shows higher morbidity in Black patients, partly because lesions are found later. Sun-exposed sites on the face and hands remain the practical target for daily protection.
A second vulnerability is pigmentary, not neoplastic. Melasma, post-inflammatory hyperpigmentation, and lichen planus pigmentosus are triggered or worsened by UV and visible light. For these conditions, sunscreen is not preventive medicine in the cancer sense. It is disease control. Visible light, particularly blue-violet wavelengths, drives melasma in darker skin types, which is why tinted formulations with iron oxides outperform clear sunscreens for that specific indication.
Acral lentiginous melanoma on palms, soles, and nails: not prevented by sunscreen, needs visual inspection Squamous cell carcinoma on ears, lips, scalp, and hands: UV-driven, higher morbidity in darker skin Melasma and post-inflammatory hyperpigmentation: triggered by UVA and visible light, sunscreen is treatment Photodermatoses such as polymorphous light eruption: can occur in any skin tone, sunscreen reduces flares Medication-induced photosensitivity: certain drugs raise UV sensitivity regardless of pigment
Misconceptions that drive underuse
The dominant misconception is that melanin is equivalent to sunscreen. It is equivalent to roughly SPF 13 in the best case, and that figure describes UVB erythema protection, not the full spectrum. Treating a built-in factor as a substitute for a product leads people to skip protection on high-exposure days and in high-altitude or reflective environments where ambient UV rises well above the conditions behind that estimate.
A second misconception is that skin cancer is rare enough in brown skin to ignore. It is less common, not rare, and the survival gap is the part that matters. Later-stage diagnosis is the dominant driver of worse outcomes, and delayed diagnosis is partly a product of low clinical suspicion on both sides of the exam room. Patients who believe they cannot get skin cancer wait longer to report changing lesions.
A third misconception concerns white cast. The belief that all sunscreens look chalky on brown skin is outdated. Chemical filters and modern micronized or dispersed mineral formulations reduce visible residue, and tinted products match a range of tones. The formulation problem is real but solvable, and it is a reason people abandon sunscreen, not a reason to skip it.
The professional caveat worth stating plainly: no sunscreen has been shown in a randomized trial to reduce melanoma mortality specifically in darker-skinned populations. The evidence base for sunscreen and skin cancer prevention is strongest for squamous cell carcinoma and actinic keratosis in lighter-skinned populations. Extrapolating to brown skin is reasonable on mechanistic grounds but rests on indirect evidence. Honest guidance acknowledges that gap rather than papering over it.
Comparing protection strategies
| Strategy | What it blocks | Practical strength | Practical limitation |
|---|---|---|---|
| Broad-spectrum SPF 30+ sunscreen | UVB and short UVA, partially long UVA | Measurable, portable, works on all tones | Needs reapplication, easy to underapply |
| Tinted sunscreen with iron oxides | UV plus visible light | Best option for melasma and pigmentary disorders | Fewer shade matches, can feel heavier |
| UPF clothing and hats | UV across the spectrum | No reapplication, no white cast | Coverage gaps at face, neck, hands |
| Shade and timing | Direct UV | Free and effective at peak hours | Scattered UV still reaches skin |
| Melanin alone | Partial UVB, weaker UVA | Always present | Roughly SPF 13, no UVA guarantee |
| Oral photoprotection (polypodium, nicotinamide) | Modest, adjunctive | Useful in some pigmentary conditions | Not a sunscreen substitute |
The table makes the tradeoffs explicit. Sunscreen is the most controllable layer and the one with the clearest dose-response for UV-driven damage. Clothing and shade require no adherence beyond behavior. Melanin is fixed and insufficient on its own. The strongest regimen stacks layers.
A timeline of what sunscreens do after application
| Time after application | What is happening | Practical implication |
|---|---|---|
| 0-15 minutes | Film forms, filters disperse | Chemical filters need time to bind skin |
| 15-30 minutes | Label SPF achieved under test conditions | Standard 2 mg/cm² dose, rarely matched in real use |
| 2 hours | Photostability begins to decline for some filters | Reapply if continuous exposure |
| 2-4 hours | Sweat and transfer degrade the film | Reapply after swimming or heavy sweating |
| Same day, evening | UV damage is cumulative, repair begins | Pigment darkening may appear within days |
| 1-4 weeks | Pigmentary disorders may flare without protection | Consistency matters more than single applications |
| Years | Cumulative UV drives photoaging and keratinocyte cancers | Daily use is the exposure variable you control |
The timeline reconciles two thresholds that often confuse people. The two-hour reapplication rule comes from FDA testing conditions and reflects film degradation, not a claim that protection hits zero at 120 minutes. The SPF number itself is measured at 2 mg/cm², roughly a quarter teaspoon for the face alone. Most people apply a fraction of that, which means real-world protection runs below the label even with perfect reapplication timing.
What to actually do
Use a broad-spectrum sunscreen labeled SPF 30 or higher on exposed skin, and treat the label as a ceiling rather than a floor. Apply about 2 mg/cm², which for the face and neck is roughly a quarter teaspoon, and extend it to ears, scalp part lines, dorsal hands, and the back of the neck. Choose a tinted formula with iron oxides if melasma or post-inflammatory hyperpigmentation is a concern.
Reapply every two hours during continuous outdoor exposure and immediately after swimming or heavy sweating. Pair sunscreen with UPF clothing, a wide-brimmed hat, and shade during peak UV hours, typically late morning to mid-afternoon depending on latitude and season. Check the UV index; above 3 warrants protection for anyone, and above 6 warrants it strongly.
Do not rely on pigment for protection during high-exposure activities such as high-altitude hiking, water sports, or snow travel, where reflected UV raises ambient dose well above sea-level norms. For acral sites, sunscreen is not the tool. Monthly self-inspection of palms, soles, and nails, plus prompt evaluation of any new or changing lesion, addresses the melanoma subtype that UV protection cannot reach.
For pigmentary conditions, consistency beats intensity. Daily application over weeks and months produces visible improvement in melasma control; sporadic high-SPF use on sunny days does not.
Limits of the evidence
The mechanistic case for sunscreen in brown skin is solid: melanin absorbs partially, UVA protection is weaker than UVB protection, and UV drives both cancer and pigmentary disease on exposed sites. The outcome evidence is thinner than the mechanism. Randomized trials of sunscreen and skin cancer prevention have enrolled predominantly lighter-skinned populations, and melanoma mortality endpoints in darker skin have not been tested directly.
What can be concluded is narrower and still actionable. Sunscreen reduces UV dose on exposed skin in every tone. That reduction is meaningful for squamous cell carcinoma risk, photoaging, and pigmentary disorders. It does not eliminate risk, it does not address acral melanoma, and it does not substitute for surveillance. The honest position is that brown skin needs sunscreen for the same reasons other skin does, with different risk priorities and a real detection gap that no topical product closes.